Katharina M. Lindner
Heidelberg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
Journal: Nature cancer
Published: August 03, 2026
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
Journal: Nature cancer
Published: October 30, 2025
ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancer.
Journal: Journal for immunotherapy of cancer
Published: July 30, 2025
Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment.
Journal: Cancer cell
Published: July 23, 2025
optiPRM: A Targeted Immunopeptidomics LC-MS Workflow With Ultra-High Sensitivity for the Detection of Mutation-Derived Tumor Neoepitopes From Limited Input Material.
Journal: Molecular & cellular proteomics : MCP
Published: April 26, 2024
H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient.
Journal: Science advances
Published: February 02, 2024
Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy.
Journal: Cell stem cell
Published: December 22, 2023
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.
Journal: Frontiers in immunology
Published: September 14, 2023
A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Journal: Nature medicine
Published: February 23, 2023
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells.
Journal: Neuro-oncology advances
Published: October 05, 2022
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.
Journal: Cancer cell
Published: May 10, 2022
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Journal: Neurological research and practice
Published: April 03, 2022
Last Updated: 09/26/2026